309-29-5
309-29-5
Chemical Structure
Doxapram
- No. CAS: 309-29-5
- Formula:C24H30N2O2
- Molecular Weight:378.51
IUPAC Name: 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenylpyrrolidin-2-one
InChIKey: XFDJYSQDBULQSI-UHFFFAOYSA-N
SMILES: O=C1N(CC)CC(CCN2CCOCC2)C1(C3=CC=CC=C3)C4=CC=CC=C4
Biological Activity: Doxapram is a respiratory stimulant. Doxapram increases breathing rate and depth by acting on the brain's respiratory centers and peripheral chemoreceptors. Doxapram inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50s of 410 nM, 37 μM, 9 μM, respectively. Doxapram inhibits the Ca²⁺-activated potassium current (IC50 ≈ 13 μM) and Ca²⁺-independent potassium current (IC50 ≈ 20 μM) in type I cells of the carotid body. Doxapram significantly prolongs the effective refractory period of the atrium and has an anti-arrhythmic effect. Doxapram can be used for the study of respiratory depression such as post-anesthesia respiratory depression, chronic obstructive pulmonary disease and apnea of prematurity[1][2][3][4][5][6].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Doxapram | 99.70% | Doxapram is a respiratory stimulant. Doxapram increases breathing rate and depth by acting on the brain's respiratory centers and peripheral chemoreceptors. Doxapram inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50s of 410 nM, 37 μM, 9 μM, respectively. Doxapram inhibits the Ca²⁺-activated potassium current (IC50 ≈ 13 μM) and Ca²⁺-independent potassium current (IC50 ≈ 20 μM) in type I cells of the carotid body. Doxapram significantly prolongs the effective refractory period of the atrium and has an anti-arrhythmic effect. Doxapram can be used for the study of respiratory depression such as post-anesthesia respiratory depression, chronic obstructive pulmonary disease and apnea of prematurity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxapram-d8 | 99.54% | Doxapram-d8 is deuterated labeled Doxapram (HY-B0551). Doxapram is a respiratory stimulant. Doxapram increases breathing rate and depth by acting on the brain's respiratory centers and peripheral chemoreceptors. Doxapram inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50s of 410 nM, 37 μM, 9 μM, respectively. Doxapram inhibits the Ca²⁺-activated potassium current (IC50 ≈ 13 μM) and Ca²⁺-independent potassium current (IC50 ≈ 20 μM) in type I cells of the carotid body. Doxapram significantly prolongs the effective refractory period of the atrium and has an anti-arrhythmic effect. Doxapram can be used for the study of respiratory depression such as post-anesthesia respiratory depression, chronic obstructive pulmonary disease and apnea of prematurity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dexetimide | 99.94% | Dexetimide ((+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide) is a piperidine anticholinergic and a high-affinity muscarinic receptor antagonist. Dexetimide can be used in studies of parkinson's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Levetimide | 99.96% | Levetimide is a potent and stereoselective inhibitor of [3H](+)pentazocine binding, with a Ki of 2.2 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-2-Ketodoxapram | (S)-2-Ketodoxapram ((S)-AHR 5955) is a metabolite of Doxapram (HY-B0551). Doxapram is a respiratory stimulant. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Ketodoxapram-d5 | 2-Ketodoxapram-d5 is deuterium labeled 2-Ketodoxapram. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxapram hydrochloride | 99.83% | Doxapram (hydrochloride) is a ventilatory stimulant. Doxapram (hydrochloride) inhibits TASK Tandem Pore (K2P) potassium channel function. Doxapram (hydrochloride) inhibits TASK-1 and TASK-3 with an EC50 values of 410 and 37 nM, respectively. Doxapram (hydrochloride) inhibits TASK-1/TASK-3 heterodimeric channel function with an EC50 value of 9 μM. Doxapram (hydrochloride) can be studied in research on apnea in preterm infants. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AD-8007 | 99.36% | AD-8007 is a blood-brain barrier-permeable ACSS2 inhibitor with human IC50 of 0.89 μM and Kd of 116.6 μM. AD-8007 reduces colony-forming ability, lipid storage levels and FASN protein expression, and induces cancer cell death. AD-8007 shrinks established tumors, acts synergistically with radiotherapy to inhibit tumor growth, reduces tumor burden, causes no obvious toxicity to normal brain tissue, and prolongs survival. AD-8007 exhibits superior metabolic stability. AD-8007 is applicable to research related to breast cancer brain metastasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(+)-Ketodoxapram | (+)-Ketodoxapram ((R)-AHR-5955) is an orally active respiratory stimulant. (+)-Ketodoxapram can be used for research on respiratory diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxapram intermediate-1 | Doxapram intermediate-1 (Compound II) is a pyrrolidinone derivative with pronounced central nervous system (CXS) and respiratory stimulation in the dog usually accompanied by varying degrees of pressor activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxapram hydrochloride hydrate (Standard) | ≥98% | Doxapram hydrochloride hydrate (Standard) is the analytical standard of Doxapram hydrochloride hydrate (HY-B0551A). This product is intended for research and analytical applications. Doxapram hydrochloride hydrate is a respiratory stimulant. Doxapram hydrochloride hydrate increases breathing rate and depth by acting on the brain's respiratory centers and peripheral chemoreceptors. Doxapram hydrochloride hydrate inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50s of 410 nM, 37 μM, 9 μM, respectively. Doxapram hydrochloride hydrate inhibits the Ca²⁺-activated potassium current (IC50 ≈ 13 μM) and Ca²⁺-independent potassium current (IC50 ≈ 20 μM) in type I cells of the carotid body. Doxapram hydrochloride hydrate significantly prolongs the effective refractory period of the atrium and has an anti-arrhythmic effect. Doxapram hydrochloride hydrate can be used for the study of respiratory depression such as post-anesthesia respiratory depression, chronic obstructive pulmonary disease and apnea of prematurity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Desmethylmoramide | Desmethylmoramide is structurally similar to known opioids. Desmethylmoramide has analgesic activity in rodents. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Cotten JF, et al. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg, 2006, 102(3), 779-785. [Content Brief]
- [2]. Peers, C., Effects of doxapram on ionic currents recorded in isolated type I cells of the neonatal rat carotid body. Brain Res, 1991. 568(1-2): p. 116-22. [Content Brief]
- [3]. Anderson-Beck, R., et al., Doxapram stimulates dopamine release from the intact rat carotid body in vitro. Neurosci Lett, 1995. 187(1): p. 25-8. [Content Brief]
- [4]. Yost CS. A new look at the respiratory stimulant doxapram. CNS Drug Rev. 2006 Fall-Winter;12(3-4):236-49. [Content Brief]
- [5]. Vliegenthart RJ, et al. Doxapram Treatment for Apnea of Prematurity: A Systematic Review. Neonatology. 2017;111(2):162-171. doi: 10.1159/000448941. Epub 2016 Oct 20. [Content Brief]
- [6]. Wiedmann F, et al. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc Res. 2022 Jun 22;118(7):1728-1741. [Content Brief]
